Development of hybrid scaffold: Bioactive glass nanoparticles/chitosan for tissue engineering applications.

Bone tissue engineering is gaining popularity as an alternative method for the treatment of osseous defects. A number of biodegradable polymers have been explored for tissue engineering purposes. A new family of biodegradable polymer/bioactive glass composite materials has been designed to be used in bone regeneration approaches. In this work, a hybrid scaffold of chitosan (CH) and bioactive glass nanoparticles (BGN) was prepared by the freeze-gelation method. This method has been studied by adjusting the concentration of acetic acid; this process can influence the structure properties of the scaffold. In this work, several BGN/CH composites have been prepared by varying the proportion of BGN in the hybrid scaffold (20, 40, 60, and 80%). Brunauer-Emmett-Teller results showed the increased surface area and porosity volume of our composite with decreasing BGN proportion. BGN/CH hybrid scaffold was characterized by using physicochemical techniques. Obtained results showed a macroporous morphology of the scaffold with a pore size of about 200 µm, and a homogeneous distribution of the BGN in the CH matrix. X-ray diffraction study confirmed the amorphous state of the BGN/CH hybrid scaffold. Interaction between CH and BGNs in the composite was confirmed. The in vitro assays showed adequate degradation properties, which is essential for the potential replacement by the new tissue. The in vitro bioactivity studies confirmed the formation of an apatite layer on the surface of the hybrid scaffold, which results in a direct bone bonding of the implant. These results indicate that BGN/CH hybrid scaffold developed is a potential candidate for bone tissue engineering.

Risedronate Effects on the In Vivo Bioactive Glass Behavior: Nuclear Magnetic Resonance and Histopathological Studies.

The present study aimed to enhance the anti-osteoporotic performance of bioactive glass (46S6) through its association with bisphosphonate such as risedronate with amounts of 8, 12, and 20%. Obtained composites have been called 46S6-8RIS, 46S6-12RIS, and 46S6-20RIS, respectively. In vitro and in vivo explorations have been carried out. Bioactive glass and risedronate association has been performed by adsorption process. Structure analyses have been carried out to evaluate and to understand their chemical interactions. Solid Nuclear Magnetic Resonance (NMR) has been employed to study the structural properties of obtained biocomposite. The spectra deconvolution showed the appearance of a species (Q 4) in the biocomposites 46S6-8RIS, 46S6-12RIS, and 46S6-20RIS indicating their successful chemical association. In vitro experiments showed the enhancement of the chemical reactivity of the composites 46S6-xRIS compared to the pure bioactive glass. In fact, the silicon liberation after 30 days of immersion was 50 ppm for pure bioactive glass 46S6, and 41, 64, and 62 from 46S6-8RIS, 46S6-12RIS, and 46S6-20RIS, respectively. Based on the in vitro results, 46S6-8RIS was implanted in the femoral condyle of an ovariectomized rat and compared with implanted pure glass in the goal to highlight its anti-osteoporotic performance. After 60 days, implanted group with 46S6-8RIS showed the increase in bone mineral density (BMD with 10%) and bone volume fraction (BV/TV with 80%) and the decrease in trabecular separation (Tb/Sp with 74%) when compared to that of 46S6 group. These results are confirmed by the histopathological analyses, which showed the bone trabeculae reconnection after the 46S6-8RIS implantation. Chemical analyses showed the reduction in silicon (Si) and sodium (Na) ion concentrations, and the rise in calcium (Ca) and phosphorus (P) ion levels, which was explained by the dissolution of biocomposite matrix and the deposition of hydroxyapatite layer. Histomorphometric results highlighted the risedronate effect on the antiosteoporotic phenomenon. Obtained results showed good behavior with only 8% of introduced risedronate in the glass matrix.